Orthocell Ltd Q4 FY26 Investor Presentation
Key points
- Record revenue of $13.2M for FY26, up 44% YoY
- Strong growth in U.S. commercialization of Remplir
- Expansion of distributor network to 20+ states
- Appointment of a Thai distributor for Remplir
- Strong growth in Australian adoption of Remplir
Full summary
Orthocell Ltd's Q4 FY26 Investor Presentation highlights a 44% year-on-year revenue growth to $13.2M for FY26, with strong commercialization of Remplir in the U.S., where the company's distributor network has expanded to 20+ states. The presentation also notes the appointment of a Thai distributor for Remplir, continued strong growth in Australian adoption of the product, and a significant expansion of the company's global footprint. The company anticipates a material uplift in U.S. revenue in the upcoming quarters, with a strong liquidity position and sufficient cash runway to support ongoing commercial execution and R&D activities.
Guidance
FY26 revenue of $13.2M, up 44% YoY; Q4 FY26 revenue of $3.8M, up 20% QoQ
Outlook
Orthocell Ltd anticipates a material uplift in U.S. revenue in the upcoming quarters, with continued expansion of its global footprint and commercialization of Remplir.
Summary generated by a large language model. Please interpret with care.